Product Refinements Can Bring Product Liability: Bayer's Yaz And Yasmin Hit With Wave of Personal Injury Suits
Entering a crowded market with a slight twist on a well-established product is often a successful strategy. But Bayer is learning what Johnson & Johnson learned: modest changes to hormonal birth control products can produce lawsuits as much as they drive sales
You may also be interested in...
Bayer’s birth control pills Yasmin and Yaz face the most pharmaceutical product liability actions in federal court followed by Pfizer’s Prempro and GlaxoSmithKline’s Avandia. While GSK has settled the bulk of cases before a single trial, Merck and Novartis are winning Fosamax and Aredia jury verdicts.
FDA has oversight over DTC advertising for Bayer’s Yaz contraceptive after the company violated an earlier agreement with state attorneys general.
Neither has announced a firm timeline, and the difference between Pfizer's 'October' and Moderna's 'November' could be mere hours or a few weeks, but Pfizer, by dint of luck or experience, is now in a position to offer the more optimistic projection on when it will seek an EUA. Both firms release their Phase III trial protocols, which seem in line with US FDA guidance.